+1 (629)348-3199A Comparative study of muscle symptoms of atorvastatin with rosuvastatin in patients of rtherosclerotic cardiovascular disease
3rd International Conference on Diabetes and Metabolism
November 29-30, 2019 | Frankfurt, Germany
Md Rakibul Hasan Rashed
Bangabandhu Sheikh Mujib Medical University, Bangladesh
Scientific Tracks Abstracts : J Diabetol
Abstract:
Statins are the corner stone therapy of atherosclerotic
cardiovascular disease (ASCVD). Statin may cause myalgia,
myotoxicity, myopathy and rhabdomyolysis along with its
lipid lowering properties and pleiotropic effects. Statins
associated muscle symptoms (SAMS) are the leading cause of
nonadherent and discontinuation. This study was conducted
to evaluate and understand the muscle symptoms of high
intensity statin therapy (atorvastatin 40 mg and rosuvastatin
20 mg) for a period of three months in individual patient with
clinical atherosclerotic cardiovascular disease. A total of 280
patients with clinical atherosclerotic cardiovascular disease
were studied to once daily atorvastatin 40 mg and rosuvastatin
20 mg. It was a randomized controlled single blind trial. The
primary end point was muscle symptoms-muscle pain, fatigue,
cramp/spasticity and weakness at 4 weeks and in 3 months of
study period. Serum creatinine kinase was measured in every
patient with muscular symptoms. Patients of atorvastatin
group noticed severe pain more than rosuvastatin group
at the end of 4 weeks and 3 months of treatment period
respectively. Significantly more patients felt extremely bad
and bad with atorvastatin compared with rosuvastatin.
Patients of atorvastatin group showed more marked increase
muscle spasm than rosuvastatin group by spasticity grade.
Three patients of atorvastatin group developed grade
3 muscle power. Serum creatine kinase > 1500 U/L was
observed more in atorvastatin than rosuvastatin group. Statin
associated muscle symptoms (more severe muscle problem,
myositis/myopathy) observed more in atorvastatin than that
of rosuvastatin group. Both treatments were well tolerated.
No cases of rhabdomyolysis, incident diabetes, hepatic or
renal insufficiency were recorded during the study period.
Rosuvastatin had better outcome profile of muscle symptoms
than atorvastatin in patients with clinical atherosclerotic
cardiovascular disease among the Bangladeshi population.
Biography:
Md Rakibul Hasan Rashed has completed my Doctor of Medicine in (MD) in Cardiology in July, 2018 from Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. He is acting as Assistant Registrar in Department of Cardiology, Rajshahi Medical College Hospital, Rajshahi, Bangladesh. He has over 6 publications that have been citied over 10 times. He is now working in a place where potential source of data exit regarding different medical issues, specially cardiology and endocrine subject. He has interest on research of medical science to contribute a bit in my sector.
E-mail: rakibulrashed.rr.20@gmail.com
PDF HTML